menu
    • menu
    [{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":1.3,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ocedurenone

    Menu

    Ocedurenone

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novo Nordisk

                            Denmark arrow
                            CPhI India 2024
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss

                            Details : KBP-5074 (ocedurenone) is a non-steroidal, mineralocorticoid receptor antagonist, was in development for patients with uncontrolled hypertension in patients with advanced chronic kidney disease.

                            Brand Name : KBP-5074

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            KBP Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            KBP Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Novo Nordisk

                            Deal Size : $1,300.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novo Nordisk to Acquire Ocedurenone for Uncontrolled Hypertension from KBP Biosciences

                            Details : Through the acquisition, Novo Nordisk gains access to KBP-5074 (ocedurenone), an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for uncontrolled hypertension with potential application in cardiovascular ...

                            Brand Name : KBP-5074

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Novo Nordisk

                            Deal Size : $1,300.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            KBP Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            KBP Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patien...

                            Details : KBP-5074 (ocedurenone) is a non-steroidal MRA which selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardiopr...

                            Brand Name : KBP-5074

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 06, 2023

                            Lead Product(s) : Ocedurenone

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth